Submitted by: N/A Last Updated by: Mark S. de Guzman 2018-06-06 14:05:37 Export to PDF

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia (XANAP)

PHRR140704-000211

Impact Study 16371

Unspecified

Xarelto® on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in Asia: A Non-interventional Study

This is an international observational study in patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism

Start Date Duration in Months Target Completion Date Actual Completion Date
2013-06-13 32 2016-02-13 0000-00-00

Completed

Institution Classification Region LTO #
Bayer Philippines, Inc. Private Business NCR CDRR-NCR-S-27
Institution Amount Region
Bayer Philippines, Inc. N/A NCR
Name E-Mail Phone Number Postal Address
Mark de Guzman mark.deguzman@bayer.com +632-5485800 29th Floor, Menarco Tower, 32nd Ave., Bonifacio Global City, Taguig
Name E-Mail Phone Number Postal Address
Mark de Guzman mark.deguzman@bayer.com +632-5485800 29th Floor, Menarco Tower, 32nd Ave., Bonifacio Global City, Taguig
Name Expertise Affiliation
Joyce Dico Go, MD Cardiologist Chinese General Hospital and Medical Center
Francis Marie Purino, MD Cardiologist University of Santo Tomas Hospital
Gilbert Vilela, MD Cardiologist Philippine Heart Center
Emma Gaspar-Trinidad, MD Cardiologist Cardinal Santos Medical Center
Rodney M. Jimenez, MD Cardiologist St. Luke's Medical Center - Quezon City
Elmer Jasper Llanes, MD Cardiologist Manila Doctors Hospital
Von Meldrick Gonda, MD Cardiologist Makati Medical Center
Project Location Institutional Ethics Review Board
Chinese General Hospital and Medical Center Chinese General Hospital and Medical Center Institutional Review Board/Independent Ethics Committee
University of Santo Tomas Hospital University of Santo Tomas Hospital Institutional Review Board
Philippine Heart Center Philippine Heart Center Ethics Review Committee
Cardinal Santos Medical Center Cardinal Santos Medical Center Ethics Review Committee
St. Luke's Medical Center - Quezon City St. Luke's Medical Center Institutional Ethics Review Board
Manila Doctors Hospital Manila Doctors Hospital Institutional Review Board
Makati Medical Center Makati Medical Center Institutional Review Board

Patients with a diagnosis of non-valvular atrial fibrillation who start treatment with rivaroxaban to prevent stroke or non-CNS systemic embolism

Adjudicated major bleeding events

All cause mortality. Adjudicated symptomatic thromboembolic events.

Completed

  • Hong Kong
  • India
  • Indonesia
  • Malaysia
  • Pakistan
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam

Clinical Trial

Unspecified

2013-06-07

None

Female and male patients ≥ 18 years of age with a diagnosis of non-valvular atrial fibrillation who start treatment with rivaroxaban to prevent stroke or non-CNS (Central Nervous System) systemic embolism, and who consent to participate in the study.

Observational

Unspecified

Unspecified

Non-randomized

Open Label

Unspecified

Single Arm

Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism observed for adjudicated major bleeding events, all cause mortality and adjudicated symptomatic thromboembolic events

Phase IV

133

184

Good recruitment rate for Philippines

13 Jun 2013

Utilization Utilization Info
No records found.

Copyright © One Window Project 2018. All rights reserved.